NEW YORK, NY, December 18, 2023 – Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-dependent improvements. Robert Barrow, Chief Executive Officer and Director of MindMed, said, “We … Continue reading MindMed Advances Treatment for Generalized Anxiety Disorder